Biotech entity
All 1 tracked stories fall under one category: pharma. Bank of America is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. CBRE Group appears in 1 tracked Biotech story from August 5, 2026.
Last mentioned: Aug 5, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Bank of America is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. The tracked stories average 2 original sources each. CBRE Group appears in 1 tracked Biotech story from August 5, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 6 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering CBRE Group. Shared-story counts are live from our verified record — not editorial picks.
Teva's fiscal 2026 EPS guidance, well below the Street's $2.17, raises red flags for biotech and pharma investors. However, a $42 average price target and stable revenue suggest a value play if the biosimilar pipeline delivers.
Source: tickerreport.com · themarketsdaily.com
CBRE Group is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
